44 related articles for article (PubMed ID: 35997717)
1. Change in disease activity needed for meaningful change in cutaneous lupus by patient characteristic: A retrospective analysis of a longitudinal database.
Kleitsch J; Pandya R; Chakka S; Yan D; Lim D; Diaz D; Feng R; Werth VP
J Am Acad Dermatol; 2024 Feb; 90(2):406-408. PubMed ID: 37806526
[No Abstract] [Full Text] [Related]
2. Obliterative Bronchiolitis as a Systemic Manifestation of Cutaneous Lupus Erythematosus.
Deshwal H; Valeria Arrossi A; Parambil JG
J Clin Rheumatol; 2021 Dec; 27(8S):S595-S597. PubMed ID: 30601199
[No Abstract] [Full Text] [Related]
3. Exacerbation of Chronic Cutaneous Lupus Erythematosus Triggered by Vaccine Against COVID-19.
Souza EN; Diniz LM; Moura LAD; Oliosi AC
Actas Dermosifiliogr; 2024 Apr; 115(4):T430-T432. PubMed ID: 38325543
[No Abstract] [Full Text] [Related]
4. Exacerbation of Chronic Cutaneous Lupus Erythematosus Triggered by Vaccine Against COVID-19.
Souza EN; Diniz LM; Moura LAD; Oliosi AC
Actas Dermosifiliogr; 2024 Apr; 115(4):430-432. PubMed ID: 36511288
[No Abstract] [Full Text] [Related]
5. Refractory cutaneous lupus erythematosus successfully treated with anifrolumab: a case series.
Martín-Torregrosa D; Mansilla-Polo M; Lasheras-Pérez MA; Botella-Estrada R; Torres-Navarro I
Int J Dermatol; 2024 Mar; 63(3):368-370. PubMed ID: 38197480
[No Abstract] [Full Text] [Related]
6. Efficacy of upadacitinib in a case of resistant lupus erythematosus tumidus.
Maione V; Bighetti S; Bettolini L; Incardona P; Calzavara-Pinton P
J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):e335-e336. PubMed ID: 37909064
[No Abstract] [Full Text] [Related]
7. Discoid lupus erythematosus of the nail treated with thalidomide.
Harp T; Woodbury MJ; Merola JF
JAAD Case Rep; 2023 Oct; 40():106-108. PubMed ID: 37771355
[No Abstract] [Full Text] [Related]
8. Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
Yuki EFN; Silva CA; Aikawa NE; Romiti R; Heise CO; Bonfa E; Pasoto SG
J Clin Rheumatol; 2021 Sep; 27(6):248-259. PubMed ID: 31693649
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Cortés-Hernández J; Ávila G; Vilardell-Tarrés M; Ordi-Ros J
Arthritis Res Ther; 2012 Dec; 14(6):R265. PubMed ID: 23217273
[TBL] [Abstract][Full Text] [Related]
10. Update on therapy--thalidomide in the treatment of lupus.
Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GR
Lupus; 2001; 10(3):188-92. PubMed ID: 11315350
[TBL] [Abstract][Full Text] [Related]
11. Clinical Images: Chronic, refractory childhood-onset cutaneous lupus erythematosus of the face responsive to lenalidomide.
Sherman MA; Srinivasalu H; Kirkorian AY; Cardis MA
Arthritis Rheumatol; 2023 Jan; 75(1):120. PubMed ID: 35997717
[No Abstract] [Full Text] [Related]
12. Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
Wu EY; Schanberg LE; Wershba EC; Rabinovich CE
Lupus; 2017 May; 26(6):646-649. PubMed ID: 27837194
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
Wang X; Li M; Zeng X; Wang Q
Rheumatology (Oxford); 2023 Oct; 62(10):e293-e294. PubMed ID: 36943383
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
